MLTX MoonLake Immunotherapeutics Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
19:20
Jun 22
Jun 22
The author defends their bullish stance on MLTX's adolescent data and dosing but clarifies they are not short, making the tweet a defensive rebuttal rather than a trade signal.
16:42
Jun 22
Jun 22
Short MLTX as the core efficacy differentiation thesis — smaller molecule size conferring superior efficacy vs. Bimzelx — has been empirically invalidated by Phase 3 results (one trial missed, the other failed to beat the comparator), removing the primary bull case.
MED
20:19
Jun 12
Jun 12
Author compares MoonLake's past strategy to what Abivax needs now, implying a structural observation rather than a current position or trade call.
LOW
01:05
May 06
May 06
Speaker highlights MLTX omitted Humira data from its own study in a cross-trial comparison, raising concerns about data presentation integrity.
HIGH
13:57
Jan 08
Jan 08
Cautionary note that clinical trial success in HS doesn't guarantee commercial uptake; Cosentyx precedent suggests bulls on MLTX may be overestimating commercial potential.
MED
13:06
Jan 08
Jan 08
MLTX had a positive trial outcome; author notes open question on how a prior failed trial will appear on the eventual drug label.
MED
About MLTX Analyst Coverage
Buzzberg tracks MLTX (MoonLake Immunotherapeutics) across 1 sources. 0 bullish vs 1 bearish calls from 1 analysts. Sentiment: mixed to bearish. 6 total trade ideas tracked. Latest voices: A May MD.